Details for Patent: 6,537,983
✉ Email this page to a colleague
Summary for Patent: 6,537,983
| Title: | Anti-inflammatory androstane derivatives |
| Abstract: | According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), whereinR1 represents C1-6 alkyl or C1-6 haloalkyl;R2 represents —C(═O)-aryl or —C(═O)-heteroaryl;R3 represents hydrogen, methyl (which may be in either the α or β configuration) or methylene;R4 and R5 are the same or different and each represents hydrogen or halogen; and {overscore (-----)} represents a single or a double bond;and salts and solvates thereof together with a long-acting β2-adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more. |
| Inventor(s): | Keith Biggadike, Paul Spencer Jones, Jeremy John Payne |
| Assignee: | GlaxoSmithKline Intellectual Property Development Ltd , SmithKline Beecham Corp |
| Application Number: | US10/066,961 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 6,537,983
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,537,983
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0108800 | Apr 07, 2001 |
International Family Members for US Patent 6,537,983
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1305329 | ⤷ Start Trial | 91429 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1305329 | ⤷ Start Trial | CA 2008 00022 | Denmark | ⤷ Start Trial |
| European Patent Office | 1305329 | ⤷ Start Trial | 300343 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
